Palisade Capital Management

mobile
news-insights-top

News & Insight

At Palisade Capital Management, we think differently than other asset managers. We believe in sharing ideas and research across teams—and now with you. Here you can gain access to our vast intellectual capital and decidedly different perspective, while seeing what we’ve been up to lately.



Monday, June 30, 2014
PCEPII Portfolio Company Brickell Biotech Announces Licensing Agreement for its Novel Retinoid Therapy with Merz North America
Posted in Private Equity News
Brickell Biotech, Inc. ("Brickell"), a clinical-stage pharmaceutical company focused on the development of differentiated, innovative, therapeutics to satisfy current unmet human needs in the global dermatology markets, today announced that it has entered into a license agreement with Merz North America, Inc. ("Merz"). The agreement grants Merz an exclusive North American license, with certain additional international rights, to develop and commercialize a completely novel retinoid compound, BBI-3000, for the treatment of skin conditions known to be responsive to retinoid agents, such as acne and psoriasis.
Tuesday, May 20, 2014
Palisade Capital Management CIO - Institutional Dennison T. Veru Appears on Fox Business “Opening Bell with Maria Bartiromo”
Posted in Media Appearances
On May 20, 2014, Palisade Capital's Chief Investment Officer - Institutional Dennison T. Veru appeared on Fox Business with Maria Bartiromo”.
Read More
Monday, April 28, 2014
PPPII Portfolio Company Promosome and GE Healthcare Life Sciences Sign Licensing Agreement
Posted in Private Equity News
GE Healthcare Life Sciences (NYSE: GE) and Promosome LLC announced today that the companies have signed a licensing agreement, granting GE Healthcare exclusive rights to an innovative suite of mammalian cell line development technologies, developed by Promosome, for increasing protein expression in mammalian cell culture. Under the terms of agreement, Promosome will receive milestone payments for technology transfer and subsequent royalties upon commercialization.
Monday, April 21, 2014
Frank Galdi joins Palisade Capital as Managing Director, Chief Risk Officer
Posted in Announcements
Frank Galdi joined Palisade Capital on April 21, 2014 as Managing Director, Chief Risk Officer. In this newly created role, Mr. Galdi will have overall responsibility for Palisade’s risk management function, including the identification and assessment of risks at the portfolio level and at a business level. Mr. Galdi will also be responsible for the management and oversight of Palisade’s performance measurement, reporting and analytics function, and the management of due diligence efforts relating to future product development and potential strategic acquisitions. Mr. Galdi will have dual reporting responsibilities to Jeffrey Serkes, Chief Operating Officer, and Dennison Veru, Executive Vice President and Chief Investment Officer.
Read More
Thursday, April 10, 2014
PCEPII Portfolio Company SEND WORD NOW® RECOGNIZED AS ‘LEADER’ IN GARTNER’S 2014 MAGIC QUADRANT FOR U.S. EMERGENCY/MASS NOTIFICATION SERVICES
Posted in Private Equity News
Send Word Now, leading worldwide provider of enterprise-class critical communications, has again been named as a ‘Leader’ in Gartner Inc.’s Magic Quadrant for U.S. Emergency/Mass Notification Services (EMNS). ‘Leaders,’ as defined by Gartner, "have products that work well for Gartner clients in midsize and large deployments. They excel in the combination of market understanding, product features and functions, and overall viability as a firm. Their EMNS products are well-known to clients, and are frequently found on RFP shortlists."
Tuesday, April 08, 2014
PCEPII Portfolio Company Mitralign Completes Enrollment in EU Study for its Novel Catheter-based Valve Repair Device: Company to seek CE Mark for new first-line percutaneous treatment of functional mitral regurgitation
Posted in Private Equity News
Mitralign Inc., a cardiac device company, announced today it has completed enrollment in a study in Europe investigating its lead device, the Mitralign System, in patients with functional mitral regurgitation (FMR). Pending successful outcomes from the study, the company will seek CE Mark approval in the European Union (EU) as a first step toward commercializing the Mitralign System. Receiving the CE Mark demonstrates that a product has been assessed by the European Commission for Enterprise and Industry and meets EU safety, health and environmental protection requirements.
‹ First  < 15 16 17 18 19 >  Last ›
Latest Research and White Papers
Friday, July 10, 2020
The Time for Convertibles is Now
We believe convertible securities, which complement other alpha-seeking strategies within a portfolio, have always been an attractive asset class and should play a vital role in strategic allocations during these unprecedented times.
Find Out More and Request This White Paper

See all Research and White Papers



Select A Category

Connect with Us

One Bridge Plaza, Suite 695, Fort Lee, New Jersey 07024 | (201) 585-7733 | Get Directions | Contact Us

Stay Informed

Sign up for our mailing list and stay up to date on the latest information and news from Palisade Capital Management.